Biodel Inc (NASDAQ:BIOD) reported financial results for the second fiscal quarter ended March 31, 2016. “As we continue to diligently evaluate strategic alternatives to …
Biodel Inc (NASDAQ:BIOD) reported financial results for the first fiscal quarter ended December 31, 2015. Corporate updates since last fiscal quarter: In October 2015, …
Biodel Inc (NASDAQ:BIOD) will present data from studies of its ultra-rapid-acting prandial/basal insulin and Glucagon Emergency Management (GEM) product candidates during the Diabetes Technology …
Biodel Inc (NASDAQ:BIOD) announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold for Biodel’s previously initiated Phase …
Biodel Inc (NASDAQ:BIOD) reported financial results for the third fiscal quarter ended June 30, 2015. Portfolio update since last fiscal quarter: Successful End-of-Phase 2 …
Biodel Inc (NASDAQ:BIOD) will present data from human and animal studies with its ultra-rapid-acting/basal insulin and glucagon product candidates during the 75th Scientific …
Biodel Inc (NASDAQ:BIOD) announced the initiation of a Phase 2b clinical trial of BIOD-531, the Company’s concentrated, proprietary, recombinant human insulin (RHI) based ultra-rapid-acting prandial/basal …
Biodel Inc (NASDAQ:BIOD) announced the appointment of Ms. Arlene M.
Biodel Inc (NASDAQ:BIOD) reported financial results for the second fiscal quarter ended March 31, 2015. Portfolio highlights since last fiscal quarter: Announced positive clinical …